SLU-PP-332 is a small-molecule drug — not a peptide — that switches on a set of nuclear receptors (the estrogen-related receptors, ERRα, β, and γ) which normally turn up the body's exercise machinery. In mice it reproduced several of the metabolic effects of physical exercise without the animal moving, which is why it is called an "exercise mimetic"1. Every result, though, comes from animals — there is no human data at all.
In plain terms: it is a drug that tells muscle cells "you just exercised" — and in mice, that was partly true. In people, it is untested.
What an "exercise mimetic" means
When you exercise, muscle cells respond by building more mitochondria and burning more fat — a program controlled in part by the estrogen-related receptors (ERRs), a family of "orphan" nuclear receptors1. The idea behind an exercise mimetic is to switch that program on with a drug instead of a workout. It is an old and appealing idea; the hard part has always been finding a molecule that does it. One naming note that trips people up: ERRs are related to the estrogen receptor by sequence but are not activated by estrogen and have nothing to do with estrogen's hormonal effects6.
How it works
SLU-PP-332 is a synthetic pan-agonist — it activates all three ERR subtypes. ERRα in particular had been notoriously hard to drug, and SLU-PP-332 stood out for hitting it1. Once activated, ERRs turn up mitochondrial biogenesis, fatty-acid oxidation, and oxidative phosphorylation — the cell's aerobic energy machinery5. In mice, a single dose triggered an acute, aerobic-exercise-like response in muscle and improved exercise capacity, and that effect depended specifically on ERRα1.
What the animal studies found
The most-cited result is metabolic. In diet-induced obese and genetically obese (ob/ob) mice, SLU-PP-332 increased energy expenditure and fat oxidation, reduced fat-mass accumulation, and improved insulin sensitivity — mimicking exercise's metabolic benefits without the exercise2. The same "turn up the mitochondria" mechanism was then tested in other organs: pan-ERR agonists improved heart failure in mice by enhancing cardiac fatty-acid metabolism and mitochondrial function3, and ERR agonism reversed mitochondrial dysfunction and inflammation in the aging kidney4. The animal picture is of a broad metabolic drug with effects across metabolic, cardiac, and renal models.
| Study | Model | Key result | Year |
|---|---|---|---|
| Billon — discovery1 | Mouse muscle | Acute ERRα-dependent aerobic-exercise response; improved exercise capacity | 2023 |
| Billon2 | Obese mice | ↑ energy expenditure & fat oxidation; ↓ fat mass; improved insulin sensitivity | 2024 |
| Xu3 | Mouse (heart failure) | Improved cardiac fatty-acid metabolism & mitochondrial function | 2024 |
| Wang4 | Mouse (aging kidney) | Reversed mitochondrial dysfunction & inflammation | 2023 |
| Billon — SLU-PP-9155 | Mice | Orally active successor enhances aerobic capacity | 2026 |
Why chase an exercise pill?
The appeal is not laziness. Many people cannot exercise enough to get its benefits — the frail elderly, and people with heart failure, muscle-wasting disease, or severe obesity — and a drug that safely reproduced even part of exercise's effect would matter for them6. That is the therapeutic vision behind ERR agonists. But the idea also comes with a warning from history: the field's best-known earlier "exercise mimetic" was abandoned after animal safety problems and now survives mainly as a banned doping substance. Enthusiasm about a mouse result is not the same as a safe, effective human medicine — a gap SLU-PP-332's own preclinical-only status makes plain.
The honest limits
Two limits define where SLU-PP-332 actually stands:
- No human data. Everything above is mouse or cell work. There are no clinical trials, no human safety data, and no approved use. The distance between a striking mouse metabolic result and a proven human drug is wide, and most compounds never cross it.
- It is not even orally active. SLU-PP-332 is poorly absorbed by mouth, so studies inject it. The same lab has since reported SLU-PP-915, a chemically distinct ERR agonist that *is* orally bioavailable and shows exercise-mimetic activity in mice5 — a sign the original molecule is a research tool, not a finished drug.
On the radar for the wrong reason
One measure of the interest around these compounds: anti-doping laboratories have already begun characterising SLU-PP-332's metabolites so they can be detected in athletes7. A drug that mimics endurance training is an obvious doping concern — and its appearance in doping-control research *before* any approved medical use captures how early and speculative this field still is.
The bottom line
SLU-PP-332 is a genuinely interesting proof of concept: a small molecule that switches on the muscle's exercise program through the ERR receptors and delivers exercise-like metabolic benefits in animals2. But it is a preclinical research compound — no human trials, not orally active, and already being superseded in the lab by newer molecules. This is an educational overview, not medical advice.